Norgine expands presence in Germany with new office opening in Wettenberg

Dutch pharmaceutical giant Norgine has inaugurated new offices in Wettenberg, Germany, marking a significant step in its ongoing growth strategy. This move strengthens its commitment to its largest product sales market, where it has been a key player since 1928. The new facility is set to enhance the company’s operations and support services, ensuring the continued delivery of high-quality healthcare solutions.

Norgine, with a history spanning over 110 years, specializes in acquiring, developing, manufacturing, and commercializing pharmaceutical products in specialist therapy areas such as gastroenterology, hepatology, cancer, and supportive care. The company’s notable presence in Germany has been fortified with a workforce of more than 100 employees engaged in various commercial, development, and support roles.

The opening of the new offices is expected to bolster the supply chain and service quality to healthcare organizations and patients across Germany. Norgine’s major products in the German market include Plenvu, Xifaxan, Movicol, Dantrium, Moviprep, and Lymphoseek, all of which play critical roles in patient care within their respective therapeutic areas.

At the opening ceremony, attended by prominent figures such as Prof. Dr. Helge Braun – the German Federal Minister for Special Affairs and Head of the Chancellery, and Thomas Brunner, Mayor of Wettenberg, Norgine CEO Peter Stein highlighted the strategic importance of the new facility: “We are confident that our new offices in Germany will help us to maintain the supply of our transformative products and high-quality service to healthcare organizations and patients. We believe that this investment will continue to support our strong ‘One Norgine’ team who share, with our partners, a vision for improving patients’ lives.”

In 2017, Norgine reported net sales of €345 million and has established a substantial commercial footprint across all major European markets. The company employs over 1,000 staff members who are integral to the development, production, marketing, sale, and distribution of its products.

This expansion not only reaffirms Norgine’s dedication to the German market but also enhances its ability to meet the growing healthcare needs in Europe. The new offices in Wettenberg are expected to serve as a vital hub for Norgine’s operations, promoting efficient workflows and fostering innovations that will continue to benefit patients regionally and globally.